Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidaemia (LLAX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02343497
Recruitment Status : Completed
First Posted : January 22, 2015
Last Update Posted : January 9, 2018
Sponsor:
Collaborators:
Institut Polytechnique LaSalle Beauvais
Naturalpha
Information provided by (Responsible Party):
Ajinomoto Foods Europe SAS

Brief Summary:
The purpose of this study is to investigate whether astaxanthin supplementation can impact triglyceride plasmatic concentrations in volunteers presenting mild dyslipidemia.

Condition or disease Intervention/treatment Phase
Dyslipidemias Dietary Supplement: Astaxanthin Dietary Supplement: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Randomized, Double-blind, Placebo-controlled, Parallel-group Design, Monocentric Study on Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidemia
Actual Study Start Date : August 2014
Actual Primary Completion Date : September 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Astaxanthin

Arm Intervention/treatment
Experimental: Astaxanthin
Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks
Dietary Supplement: Astaxanthin
Placebo Comparator: Placebo
filling agent, in lipid capsules, 2 caps per day, duration 12 weeks
Dietary Supplement: Placebo



Primary Outcome Measures :
  1. fasting plasma triglycerides [ Time Frame: 0, 12 weeks ]
    g/l


Secondary Outcome Measures :
  1. fasting cholesterol [ Time Frame: 0, 12 weeks ]
    total cholesterol (g/l)

  2. fasting HDL-cholesterol [ Time Frame: 0, 12 weeks ]
    g/l

  3. fasting LDL-cholesterol [ Time Frame: 0, 12 weeks ]
    g/l

  4. apolipoprotein A1 [ Time Frame: 0, 12 weeks ]
    g/l

  5. apolipoprotein B [ Time Frame: 0, 12 weeks ]
    g/l

  6. apolipoprotein balance [ Time Frame: 0, 12 weeks ]
    Apolipoprotein B over Apolipoprotein A1 ratio

  7. resting blood pressure [ Time Frame: 0, 6, 12 weeks ]
    triplicate measure

  8. resting heart rate [ Time Frame: 0, 6, 12 weeks ]
  9. fasting glucose [ Time Frame: 0, 12 weeks ]
    g/l

  10. fasting insulin [ Time Frame: 0, 12 weeks ]
    mU/l

  11. homeostatic model assessment to quantify insulin resistance (HOMA-IR) [ Time Frame: 0, 12 weeks ]
    glucose (mg/dl) * insulin(U/l) / 405

  12. fasting adiponectin [ Time Frame: 0, 12 weeks ]
    flow cytometry

  13. fasting leptin [ Time Frame: 0, 12 weeks ]
    flow cytometry

  14. fasting ghrelin [ Time Frame: 0, 12 weeks ]
    flow cytometry

  15. fasting resistin [ Time Frame: 0, 12 weeks ]
    flow cytometry

  16. phosphatidylcholine hydroperoxides [ Time Frame: 0, 12 weeks ]
    HPLC/MS

  17. plasmatic concentrations in astaxanthin [ Time Frame: 0, 6, 12 weeks ]
    HPLC/MS

  18. compliance with study product [ Time Frame: 0, 6, 12 weeks ]
    accountability of returned used/unused caps

  19. adverse events [ Time Frame: during the 12 weeks of intervention ]
    number of subjects with adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

To be fulfilled at V0:

  1. Male and female volunteers, able to read and write, aged from 18 to 60 years inclusive at time of screening.
  2. Smokers and no smokers.
  3. Subject with a good physical condition confirmed based on the subject's interview and the clinical exam performed by the investigator.
  4. Subject with a Body Mass Index (BMI) ≥ 18,5 and < 35 kg/m².
  5. Written informed consent provided prior to screening, after receiving and understanding the subject information.
  6. Stable body weight (< 3% variation) within the last 3 months prior to screening.
  7. Subject registered with the French Social Security, in agreement with the French law on biomedical experimentation.

    To be fulfilled before V1, randomization visit:

  8. Subject with fasting triglyceride concentration ≥ 1.2 and < 4 g/l.
  9. Subject with fasting serum LDL-cholesterol ≤ 2.2 g/l.

Exclusion Criteria:

To be fulfilled at V0:

  1. Subject taking lipid altering drug therapy within 6 weeks prior to screening. Also excluded are supplements known to have significant lipid altering effects, such as:

    • Phytosterols or phytostanols,
    • Red yeast rice extract (Monascus purpureus),
    • Beta-glucans,
    • Omega-3 fatty acids (alpha-linolenic, docosahexaenoic and eicosapentaenoic),
  2. Subject using the following medications: systemic corticosteroids (nasal and inhaled corticosteroids are permitted), orlistat, bile acid resins, prescription omega-3 fatty acids, cyclical or non continuous hormone therapy (estrogen or testosterone) excepted stable oestroprogestative or progestative contraception i.e. started at least three months preceding the screening visit.
  3. Intake of oestroprogestative or progestative contraception started within less than three months preceding the screening visit.
  4. Subject taking antioxidant agents or vitamins within 6 weeks prior to screening.
  5. Subject taking astaxanthin-rich foods (red fish and seafood, mostly) or supplements (including krill).
  6. Subject following any special diet including, but not limited to liquid, high or low protein, raw food, vegetarian or vegan, etc.
  7. Subject with any sensitivity or allergy to any of the products used in this clinical trial.
  8. Subject that consume more than three (3) units of alcoholic beverage daily. For the purpose of this study, a unit of alcohol is defined as 400 ml of beer, 200 ml of wine or 50 ml of hard spirits.
  9. Subject with known human immunodeficiency virus (HIV) seropositivity.
  10. Women who are pregnant or breastfeeding, or planning a pregnancy during the duration of the study.
  11. Female subject without efficient contraceptive method: hormonal contraception (including patch, contraceptive ring, etc.), intra-uterine device or other mechanical contraception method (condom or diaphragm) or spermicide for all the duration of the study.
  12. Subject treated for type 1 or type 2 diabetes mellitus.
  13. Subject with known cardiovascular disease or stroke, except for conditions that are deemed clinically insignificant by the investigator.
  14. Subject with symptomatic hypertension, treated or not.
  15. Subject treated by antivitamin K.
  16. Subject with history of significant gastrointestinal disease such as severe constipation, diarrhea, malabsorptive disease, inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis) and all kind of gastrointestinal surgery.
  17. Subject with thyroid dysfunction or treatment for this pathology.
  18. Subject with history of severe psychiatric illness which in the opinion of the investigator would interfere with the optimal participation in the study.
  19. Subject with history of cancer within 5 years of screening visit (except for successfully treated basal and squamous cell carcinoma of the skin).
  20. Subject with any medical contraindication to blood sampling (anemia, clotting defect).
  21. Subject practicing intense physical activity (sport, physical exertion at work).
  22. Subject with history of drug abuse.
  23. Participation to any other clinical trial simultaneously and/or within 1 month prior to screening.
  24. Subject who in the opinion of the investigator have a risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trial.
  25. Subject of legal age unable of giving consent.
  26. Subject deprived of liberty by judicial or administrative decision.
  27. Subject of legal age under legal protection.
  28. Subject having received over 4500 euros for clinical trial participation within the prior year including the indemnity for the present study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02343497


Locations
Layout table for location information
France
Centre Nutrition Clinique Naturalpha
Lille, France, 59020
Sponsors and Collaborators
Ajinomoto Foods Europe SAS
Institut Polytechnique LaSalle Beauvais
Naturalpha
Layout table for additonal information
Responsible Party: Ajinomoto Foods Europe SAS
ClinicalTrials.gov Identifier: NCT02343497    
Other Study ID Numbers: 2014-A00198-39
First Posted: January 22, 2015    Key Record Dates
Last Update Posted: January 9, 2018
Last Verified: January 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases